High incidence of chronic lymphocytic leukemia (CLL) diagnosed by immunophenotyping: A population-based Canadian cohort

Seftel, Matthew D.; Demers, Alain; Banerji, Versha; Gibson, Spencer B.; Morales, Carlos Andrés Collazos; Musto, Grace; Pitz, Marshall; Johnston, James B.

doi:10.1016/j.leukres.2009.06.013

Cited by 52 publications

(41 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, the under-reporting estimates were as high as 63 % (unmatched cases). This higher underreporting compared with prior studies may be a result of capturing data directly from physician practices instead of relying only on laboratory data [13,14].…”

Section: Discussionmentioning

confidence: 71%

“…In addition to the generic categories for Hodgkin's Lymphomas, non-Hodgkin's lymphomas (NHL), myelomas and leukemias, we separately examined chronic lymphocytic leukemia (CLL) as a distinct category. This is the most common adult ''leukemia'' in the United States [13,14,19,32,33]. Further, patients with CLL may be routinely followed without receiving treatment for many years [14,19,22,32,33].…”

Section: Hematologic Malignancy Categorizationmentioning

confidence: 99%

“…The continued reliance on hospital-based reporting results in those cases diagnosed and/or treated exclusively in the physician office setting to be unreported or to have significant delays in reporting [2,[8][9][10][11][12]. Reporting of hematologic malignancies is an increasingly important focus for cancer surveillance because hematologic malignancies in particular may be diagnosed and treated in the outpatient setting, resulting in substantially higher rates of under-reporting of these cancers estimated to be as much as 18-37 % [13][14][15][16][17][18]. Further patients may be followed for extended periods by watchful waiting [13-16, 18, 19] further reducing the likelihood of reporting through traditional methods.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Hematologic malignancies: an opportunity to fill a gap in cancer surveillance

Penberthy

McClish

Peace

et al. 2012

Cancer Causes Control

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 71%

Section: Hematologic Malignancy Categorizationmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Hematologic malignancies: an opportunity to fill a gap in cancer surveillance

Penberthy

McClish

Peace

et al. 2012

Cancer Causes Control

View full text Add to dashboard Cite

show abstract

“…In Canada, the median age at diagnosis of cll is approximately 72 years, with fewer than 2% of cases occurring in patients under 50 years of age 8 . Given that most patients with cll are elderly, the efficacy of treatment needs to be balanced against patient tolerance.…”

Section: Goals Of Treatmentmentioning

confidence: 99%

A Canadian Perspective on Bendamustine for the Treatment of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

et al. 2012

View full text Add to dashboard Cite

Despite the success of standard treatments in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), patients are often unable to tolerate aggressive regimens, and they require effective alternatives. Bendamustine is a bifunctional alkylator with unique properties that significantly distinguish it from other agents in its class. In untreated CLL, bendamustine has demonstrated rates of response and progression-free survival (PFS) that are superior to those with chlorambucil, with an acceptable toxicity profile. In the relapsed setting, combination treatment with bendamustine–rituximab (BR) has demonstrated promising activity in high-risk patients such as those refractory to fludarabine or alkylating agents. In untreated patients with indolent NHL and mantle cell lymphoma, BR has demonstrated a PFS significantly longer than that achieved with R-CHOP (rituximab–cyclophosphamide–doxorubicin–vincristine–prednisone), with significantly reduced toxicity. In the relapsed setting, BR has demonstrated rates of response and PFS superior to those with fludarabine–rituximab, with comparable toxicity. In the United States and Europe, bendamustine has been approved for the treatment of CLL and indolent NHL; its approval in Canada is pending and eagerly awaited. Once available, bendamustine will benefit many Canadian patients with NHL and CLL.

show abstract

“…The median age of onset ranges between 70 and 75 years 2 . A recent Canadian study described the underreporting of cll cases in cancer registries and determined the prevalence of cll to be 7.99 per 100,000 population 3 . According to the Canadian Cancer Society, approximately 2395 new cases of cll were diagnosed in 2013 in Canada 4 .…”

Section: Introductionmentioning

confidence: 99%

Examining the Medical Resource Utilization and Costs of Relapsed and Refractory Chronic Lymphocytic Leukemia in Ontario

et al. 2017

View full text Add to dashboard Cite

PurposeThe purpose of the present study was to collect medical resource utilization data and costs in Ontario for the management of patients with relapsed or refractory chronic lymphocytic lymphoma (cll) who have undergone at least 1 treatment course and have been stratified by Rai staging.Methods This retrospective longitudinal cohort study, conducted by chart review, analyzed anonymized patient records from two cancer centres in Ontario. Comprehensive records of 86 patients meeting the inclusion criteria were used to obtain resource utilization, which, multiplied by unit costs, were used to determine overall and mean costs. Descriptive statistics are presented for patient demographics, medical resource utilization, and costing data. ResultsThe total cost for the cohort was $2.2 million over a mean follow-up period of 4.7 years. The mean total cost per patient (regardless of follow-up) was $25,736. In terms of Rai staging, overall mean costs were highest for stage iv patients. Almost 50% of the total cost was attributable to cll treatments, among which fludarabine-based treatments had the highest utilization. ConclusionsFor this Canadian cll cohort, medical resource utilization and costs were determined to be $2.2 million, with cll treatments accounting for about half the cost. Costs generally increased with Rai stage.

show abstract

High incidence of chronic lymphocytic leukemia (CLL) diagnosed by immunophenotyping: A population-based Canadian cohort

Cited by 52 publications

References 23 publications

Hematologic malignancies: an opportunity to fill a gap in cancer surveillance

Hematologic malignancies: an opportunity to fill a gap in cancer surveillance

A Canadian Perspective on Bendamustine for the Treatment of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

Examining the Medical Resource Utilization and Costs of Relapsed and Refractory Chronic Lymphocytic Leukemia in Ontario

Contact Info

Product

Resources

About